Ascentage Pharma Changes Company Secretary

Ticker: AAPG · Form: 6-K · Filed: Feb 25, 2025 · CIK: 2023311

Sentiment: neutral

Topics: corporate-governance, filing-update

TL;DR

Ascentage Pharma swapped out their Company Secretary and Authorized Rep on Feb 25.

AI Summary

On February 25, 2025, Ascentage Pharma Group International announced a change in its Company Secretary and Authorized Representative. This update was formally communicated through a Hong Kong Stock Exchange announcement, which is attached as Exhibit 99.1 to their Form 6-K filing.

Why It Matters

Changes in key corporate officers like the Company Secretary can impact regulatory compliance and communication channels for investors.

Risk Assessment

Risk Level: low — This filing reports a routine administrative change in corporate officers, not a material financial event.

Key Players & Entities

FAQ

What was the specific announcement made by Ascentage Pharma on February 25, 2025?

Ascentage Pharma Group International issued a Hong Kong Stock Exchange announcement titled 'CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE'.

Where can a copy of this announcement be found?

A copy of the Hong Kong Stock Exchange announcement is attached as Exhibit 99.1 to this Form 6-K filing.

What is the Commission File Number for Ascentage Pharma Group International?

The Commission File Number for Ascentage Pharma Group International is 002-023311.

What is the principal executive office address for Ascentage Pharma Group International?

The principal executive offices are located at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China.

Does Ascentage Pharma file annual reports under Form 20-F or 40-F?

Ascentage Pharma indicates it files annual reports under cover of Form 20-F.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on February 25, 2025 regarding ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing